AC Immune reports 12-month interim data from ACI-24 Alzheimer's trial
Tweet Send to a Friend
AC Immune SA (NASDAQ: ACIU) announced interim 12-month data from the first three cohorts of its Phase 1b/2 ABATE trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
